` KLTO (Klotho Neurosciences Inc) vs S&P 500 Comparison - Alpha Spread

KLTO
vs
S&P 500

Over the past 12 months, KLTO has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +17% growth.

Stocks Performance
KLTO vs S&P 500

Loading
KLTO
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
KLTO vs S&P 500

Loading
KLTO
S&P 500
Difference
www.alphaspread.com

Performance By Year
KLTO vs S&P 500

Loading
KLTO
S&P 500
Add Stock

Competitors Performance
Klotho Neurosciences Inc vs Peers

S&P 500
KLTO
ABBV
CYTH
AMGN
GILD
Add Stock

Klotho Neurosciences Inc
Glance View

Market Cap
66.7m USD
Industry
Biotechnology

Klotho Neurosciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in New York City, New York. The company went IPO on 2022-04-29. Klotho Neurosciences, Inc. is a biopharmaceutical company. The firm is engaged in the development of disease-modifying cell and gene therapies using a patented secreted form of the anti-aging Klotho gene (s-KL) to transform the treatment of neurodegenerative and age-related disorders, such as amyotrophic lateral sclerosis (ALS), Alzheimer's, and Parkinson's disease. The Company’s portfolio consists of its proprietary cell and gene therapy programs using deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) as therapeutics and diagnostics. Its gene therapy programs include KLTO-202, KLTO-101, and KLTO-301. Other assets include clinical-stage programs involving antibody biologics targeting cancer and autoimmune diseases, and drug delivery via a needle-free dry powder jet autoinjector called Nanoject. The firm has licensed the anti-aging protein called α-Klotho for gene therapy to stop the progression of, or prevent, neurodegenerative diseases.

KLTO Intrinsic Value
Not Available
Back to Top